Marketing: Page 2
-
Permission granted by Pear Therapeutics
Pear Therapeutics undergoes another round of layoffs, cutting 22% of staff
The digital therapeutics company said the reductions will extend its cash runway and curb its reliance on financing.
By Elise Reuter • Nov. 15, 2022 -
Courtesy of GSK Flickr page
Under FDA pressure, GSK limits use of ovarian cancer drug
The drugmaker’s decision is the latest fallout from safety concerns that have emerged in testing of so-called PARP inhibitors, resulting in withdrawals by Merck & Co., AstraZeneca and Clovis Oncology.
By Jonathan Gardner • Nov. 11, 2022 -
Courtesy of EQRx
EQRx redraws ‘radical’ drug pricing plans for first two drugs
The buzzy startup, which planned to undercut big pharma on price, also dropped plans to seek U.S. approval in lung cancer of an immunotherapy competitor to Keytruda.
By Jonathan Gardner • Nov. 10, 2022 -
Novo Nordisk
Obesity drugsNovo obesity drug sales lag as manufacturing problems persist
Manufacturing problems continue to weigh on Novo’s Wegovy launch as competition looms from Eli Lilly’s fast-selling diabetes medicine Mounjaro.
By Jonathan Gardner • Nov. 2, 2022 -
Lilly sales of new diabetes drug accelerate on rising patient demand
Company executives highlighted the “viral nature” of demand for Mounjaro, which was approved in May for diabetes and has also shown a strong weight-loss benefit in clinical testing.
By Ned Pagliarulo • Nov. 1, 2022 -
Gilead Sciences Inc. / Kite Pharma
Gilead, fueled by latest approval, sees CAR-T sales take off
After a slow start, Gilead’s CAR-T business is growing fast, enabling it to pull ahead of rival cell therapy developers like Bristol Myers Squibb and J&J.
By Jacob Bell • Oct. 28, 2022 -
Novartis
Novartis sales of Zolgensma gene therapy slow as market shifts
Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.
By Ned Pagliarulo • Oct. 25, 2022 -
Finbarr Webster via Getty Images
Pfizer planning steep price hike for COVID-19 vaccine
The company is considering charging as much as between $110 and $130 per dose — roughly four times the vaccine’s current price — once sales transition to the private market.
By Ned Pagliarulo • Oct. 21, 2022 -
Alarmy.com/Yuri Arcurs
Sponsored by First Republic BankBuilding the dream team: How life science startups can attract top talent
Learn how to attract and retain top talent, in an ultra-competitive labor market.
By Nishta Rao, Managing Director, Life Science, First Republic Bank • Oct. 17, 2022 -
Courtesy of GoodRx
GoodRx launches new push to draw in doctors
Targeting providers directly is a pivot for GoodRx, but the company sees an opportunity to capture more pharmaceutical advertising revenue, said executive Preeti Parikh.
By Hailey Mensik • Oct. 13, 2022 -
Sarah Silbiger via Getty Images
Omicron boosters from Pfizer, Moderna cleared by FDA for younger children
Pfizer's reformulated vaccine is now authorized for use in children at least 5 years of age, while Moderna's will be available for kids as young as 6.
By Ned Pagliarulo • Oct. 12, 2022 -
Obesity drugs
Lilly looks to speed FDA review of new diabetes drug in obesity
A new fast track designation allows Lilly to begin the process of seeking approval of tirzepatide for obesity, though the drug will need to succeed in a second trial to get to market.
By Jonathan Gardner • Oct. 6, 2022 -
Permission granted by Biogen
Biogen to pay $900M to settle lawsuit over MS drug outreach
A former Biogen employee sued in 2012, alleging the company paid physician fees to encourage prescribing of its drugs. Biogen did not admit wrongdoing as part of the settlement.
By Christopher Newman • Sept. 27, 2022 -
Sponsored by flipMD from GoodRx
Optimizing pharmaceutical innovation
Elevate pharma product development and marketing through collaboration with physician experts
Sept. 19, 2022 -
Courtesy of Sanofi
Sanofi, AstraZeneca secure EMA support for RSV drug in babies
If authorized by the European Commission, the companies’ antibody medicine would become the first cleared for broad use in newborns and infants.
By Jonathan Gardner • Sept. 16, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers gets FDA approval for new type of psoriasis drug
Sotyktu has been on the pharma’s top pipeline candidates and its clearance continues a string of positive regulatory news for the company.
By Jonathan Gardner • Updated Sept. 12, 2022 -
Sarah Silbiger via Getty Images
FDA names new head to vaccine review office
David Kaslow, the lead scientist at a global public health nonprofit, will succeed Marion Gruber, who retired last fall amid her dissent on the timing of COVID-19 vaccine boosters.
By Jonathan Gardner • Sept. 9, 2022 -
Getty Images
FDA holds back Alvotech’s Humira biosimilar over manufacturing issues
The company received a complete response letter, but still expects to win approval of the copycat drug in time to launch it in the U.S. next year.
By Jonathan Gardner • Sept. 6, 2022 -
Joe Raedle/Getty Images via Getty Images
Funds for free COVID-19 vaccines could run out as early as January, HHS says
The commercial market for COVID-19 vaccinations could be similar to that for seasonal flu shots and other vaccines, an official with the department said.
By Sydney Halleman • Aug. 31, 2022 -
Jacob Bell / BioPharma Dive
Incyte secures second approval for targeted cancer drug
Sold as Pemazyre, the drug, which blocks well-known cancer proteins known as FGFRs, is now also cleared for use in certain patients with very rare and aggressive blood cancers.
By Jacob Bell • Aug. 29, 2022 -
24K-Production via Getty Images
Sponsored by Worldwide Clinical TrialsPsychedelic clinical trials: What sponsors should know when designing new protocols
With regulators and lawmakers seemingly on board, sponsors have more opportunities than ever to pursue clinical research in this high-velocity area.
Aug. 29, 2022 -
Gabriel Kuchta via Getty Images
Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology
The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology.
By Jonathan Gardner • Aug. 26, 2022 -
Jacob Bell
Novartis begins plans to spin off generic drug business
After reviewing multiple options including a possible sale, the Swiss drugmaker said spinning off Sandoz would give the division “greater freedom to operate” and capitalize on newly growing sales.
By Jonathan Gardner • Aug. 25, 2022 -
Permission granted by Gilead Sciences
Gilead breaks through with first approval for new HIV drug
European authorities cleared Gilead’s long-acting shot for patients whose HIV infection is resistant to other drugs. An FDA decision is expected by December.
By Jonathan Gardner • Aug. 22, 2022 -
Permission granted by Akili Interactive
Digital medicine company Akili gets cold market reception after blank-check merger
After spiking on news of the merger’s close, shares in the ADHD treatment developer fell sharply in trading.
By Elise Reuter • Updated Aug. 23, 2022
Previous
